Skip to Content

Deucravacitinib, A New Oral Option for Patients with Moderate to Severe Psoriasis

Deucravacitinib provides an effective treatment for moderate to severe psoriasis patients and is long-term safe for four years.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top